Ferguson Enterprises Inc. Common Stock vs Novavax Inc — how do they compare? Ferguson Enterprises Inc. Common Stock trades at $228.4 (market cap $43.13B), while Novavax Inc trades at $12.4 (market cap $2.08B). The key difference: Ferguson Enterprises Inc. Common Stock is far larger — about 20.7× Novavax Inc's market cap, and Ferguson Enterprises Inc. Common Stock pays a 1.6% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ferguson Enterprises Inc. Common Stock for 0 Days and Novavax Inc for 59 Days on average.
| FERG | NVAX | |
|---|---|---|
Market Cap | $43.13B | $2.08B |
Volume | 1,358,634 | 8,501,139 |
Sector | Industrials | Health |
52-Week High | $267.71 | $12.82 |
52-Week Low | $214.26 | $6.22 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $49.58B | $1.66B |
Dividend Yield | 1.6% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $12.82, up 1.26% with a bullish technical outlook. The company reported strong revenue of $1.12B in 2025 and net income of $440.30M, marking a significant turnaround. Recent earnings beats and FDA approvals for updated COVID-19 vaccines support momentum. However, negative cash flow and high debt levels pose challenges.
The outlook is mixed: analyst consensus is 74% Buy with bullish technical signals, but profitability remains volatile. Key risks include cash burn and competitive pressure. Upside depends on successful Matrix-M platform adoption and partnership execution. Investors should weigh strong recent performance against fundamental weaknesses.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Ferguson Enterprises, Inc. distributes plumbing, HVAC, waterworks, and related building products to professional contractors, builders, and facility managers across North America, operating through branches, showrooms, and digital commerce.
Read more on FERG →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →